New drug cocktail shows promise for tough bile duct cancer
NCT ID NCT07619937
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tested a three-drug combination—chemotherapy infused into the liver, an immunotherapy drug (tislelizumab), and a targeted pill (regorafenib)—as a first treatment for 31 people with advanced bile duct cancer that couldn't be removed by surgery. The goal was to see how many patients' tumors shrank and how long they lived without the cancer growing. Researchers also tracked side effects. The study is complete, but results are not yet published.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- hepatic arterial infusion chemotherapy, tislelizumab, and regorafenib
- What this could lead to
- If this combination works, it could offer a new first-line treatment option for people with advanced bile duct cancer, potentially shrinking tumors and extending life.
- What could go wrong
- This is a small, single-center, single-arm phase II trial with only 31 participants, so results may not apply broadly. The combination also carries risks of side effects from chemotherapy, immunotherapy, and targeted drugs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450052, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A new test could reveal how radiation affects the liver
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- Can a smart drug home in on Hard-to-Treat GI cancers?
- Can matching drugs to tumor genes beat biliary cancer?
- Can a new drug ST316 shrink Hard-to-Treat tumors?
- Web tool aims to empower rare cancer patients in genomic choices